News

Keep up to date with our recent breakthroughs and partnerships as we develop novel life changing therapeutics for a range of inflammatory and fibrotic diseases.

Latest updates

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications 

Oslo, Norway, 23 October 2024: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory...

Read more
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

Executive appointments will drive growth strategy and progression of clinical pipeline Oslo, Norway and Boston, MA, 9 October 2024: Calluna...

Read more
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance

First senior executive appointment made following Company launch to oversee strategic development of clinical programs

Read more
News Placeholder
Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx) announced their merger to form Calluna Pharma Inc.

Read more

Download Our Investor Presentation

Download presentation

"*" indicates required fields

Calluna Pharma will use the contact details you provide to contact you with regards to offering further information, as well as to keep you updated on our latest developments. You may unsubscribe at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.